EUCTR2014-002155-25-GB进行中（未招募）1 期
An Open-Label, Phase 2a Study to Evaluate the Pharmacodynamics of Different Dosing Regimens of TAK-448, a Kisspeptin Agonist, in Male Overweight/Obese Subjects With Hypogonadotropic Hypogonadism
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1.In the opinion of the investigator, the subject is capable of understanding and complying with protocol requirements.
- •2.The subject or, when applicable, the subject’s legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
- •3.The subject has two morning total ST concentrations of =12.0 nmol/L ( =3.46 ng/mL) taken during the Screening period.
- •4.The subject is male and aged 18 to 60 years, inclusive.
- •5.The subject has a body mass index (BMI) between 25.0 and 50.0 kg/m2, inclusive.
- •6. If diagnosed with T2DM, the subject has a HbA1c concentration <12% at Screening and is on a stable dose of diabetes therapies (including insulin and/or glucagon-like peptide-1 therapies).
- •7.The subject has a LH concentration <8 IU/L at Screening.
- •8.A male subject who is nonsterilized* and sexually active with a female partner of childbearing potential* agrees to use adequate contraception* from signing of informed consent throughout the duration of the study and for 12 weeks after last dose.
- •*Definitions and acceptable methods of contraception are defined in Section 9.1.10 Contraception and Pregnancy Avoidance Procedure and reporting responsibilities are defined in Section 9.1.11 Pregnancy of the protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 48
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.The subject has received any investigational compound within 30 days prior to Screening.
- •2.The subject has received TAK-448 in a previous clinical study, or previous cohort.
- •3.The subject is an immediate family member, study site employee, or is in a dependant relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.
- •4.The subject has uncontrolled, clinically significant neurologic, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, or endocrine disease or other abnormality (other than T2DM, its complications and associated conditions), which may impact the ability of the subject to participate or potentially confound the study results.
- •5.The subject has a recent history or clinical manifestations of significant CVD – such as a history of myocardial infarction or stroke in the 6 months preceding the Screening visit or has untreated peripheral arterial disease.
- •6.The subject has a history of hypersensitivity or allergies to any component of the formulation of TAK-448.
- •7.The subject has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 5 years prior to Screening.
- •8.The subject is required to take excluded medications, supplements, or food products listed in Section 7.3.
- •9.The subject intends to donate sperm during the course of this study or for 12 weeks after the last dose of study drug.
- •10.The subject has clinical evidence of anatomic or pathological hypothalamic/pituitary disease.
- •11.There is any finding in the subject’s medical history, physical examination, or safety laboratory tests giving reasonable suspicion of a disease that would contraindicate taking TAK-448, or a similar drug in the same class that might interfere with the conduct of the study.
- •12.The subject has a history of cancer (including prostate cancer), with the exception of basal cell carcinoma which has been in remission for at least 5 years prior to Screening.
- •13.The subject has a history of or present symptomatic prostate disease (including benign prostatic hyperplasia) or PSA is >4 ng/mL at Screening.
- •14.The subject has a known history of human immunodeficiency virus infection at Screening.
- •15.The subject is deemed by the study team to have poor peripheral venous access.
- •16.The subject has donated or lost 450 mL or more of his blood volume (including plasmapheresis), or had a transfusion of any blood product within 45 days prior to Screening, or is planning to donate blood for 12 weeks after the last dose of study medication.
- •17.The subject has a Screening or Day -1 abnormal (clinically significant) ECG. Entry of any subject with an abnormal (not clinically significant) ECG must be approved, and documented by signature of the principal investigator or medically qualified subinvestigator.
- •18.The subject has abnormal Screening or Day -1 laboratory values that suggest a clinically significant underlying disease or subject with the following lab abnormalities: alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) >2× the upper limits of normal (ULN).
- •19.The subject, in the opinion of the investigator, is unlikely to comply with the protocol or is unsuitable for any other reason.
- •20.The subject has had more than two severe hypoglycemic events (requiring third party assistance) within 6 months prior to the Screening Visit.
- •21.The subject has a diagnosis of type 1 diabetes me
研究者
相似试验
进行中（未招募）
不适用
A Phase 1 study of the body and tumour effects of CUDC-101 in HER2 positive breast cancer patientsEUCTR2012-003064-47-GBCuris, Inc.
进行中（未招募）
1 期
Research done in healthy human volunteers to Investigate how the MK-8342B (ENG-E2, 125/300 µg/day) Vaginal Ring behaves in and influences the body of female Postmenarcheal Adolescents and Healthy Female Adults.Hormonal contraception and primary dysmenorrhea in woman seeking contraception.MedDRA version: 19.0Level: LLTClassification code 10073728Term: Hormonal contraceptionSystem Organ Class: 100000004865EUCTR2015-005284-16-ATMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
已完成
不适用
A Phase I, Open-Label Study to Investigate the Pharmacodynamics and Pharmacokinetics of Etonogestrel (ENG) and 17*-Estradiol (E2) in Healthy Young Adult Women Following Administration of MK-8342B (ENG-E2, 125/300 *g/day) Vaginal Ring for an Extended Period of Timedysmenorrheahormonal contraception and primary dysmenorrhea in womencontraceptionNL-OMON43028Merck Sharp & Dohme (MSD)20
已完成
1 期
Pharmacokinetics of Miist Nicotine Inhaler in healthy smokersSmoking cessationMental Health - AddictionACTRN12623001317684Miist Therapeutics South Pty Ltd10
进行中（未招募）
1 期
A PROSPECTIVE, OPEN-LABEL STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY & EFFICACY OF ANIDULAFUNGIN WHEN USED TO TREAT CHILDREN WITH INVASIVE CANDIDIASIS, INCLUDING CANDIDEMIAINVASIVE CANDIDIASIS, INCLUDING CANDIDEMIAMedDRA version: 9.1Level: LLTClassification code 10064954Term: Invasive candidiasisEUCTR2008-004150-32-GRPfizer Inc, 235 East 42nd Street, New York, NY 1001730